MEETING ACCREDITATION INFORMATION

ACTIVITY TITLE

Women's Cardiometabolic Health and Wellness Masterclass

ACTIVITY DATE

September 9-11, 2022 Rancho Palos Verdes, CA

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based based cardiologists, endocrinologists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, physician assistants, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the symptoms and clinical presentation of acute and chronic cardiovascular diseases in women, including heart failure, valvular disease, and acute coronary syndromes.
- List unique CVD risk factors in women across the age spectrum.
- Describe the risk of cardiometabolic disease in women due to PCOS and adverse pregnancy outcomes.
- Outline the cardiometabolic safety of postmenopausal hormone therapy and contraception.
- Select individualized approaches for the screening and co-management of cardiometabolic risk and women's health, including PCOS, postmenopausal symptoms, contraception, osteoporosis, infertility, and long-term pregnancy adverse outcomes.

JOINT PROVIDERSHIP STATEMENT







In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 4.25 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 4.25 contact hour(s) (0.575 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-22-176-L01-P) Type of Activity: Knowledge

HOW TO REQUEST CE CREDIT

Learners may earn up to a maximum of 6.5 AMA/ACPE/ANCC/CDR credits for attending all General Sessions (earn up to 4.25 hours) and CME Satellite Symposia (earn up to 2.25 hours). For educational symposia support information, including accreditation, please review the CME symposia information on the mobile app under the **CME & PME Symposia** button.

An evaluation link will be provided post-meeting to all attendees of the Masterclass. Several email reminders will be sent post-meeting. Please claim your CE credits by completing the evaluation by Friday, September 30, 2022.

Upon completion of the CME/CE evaluation, attendees can download their general sessions certificate. For satellite symposia, certificates will be provided separately via email within 5-7 business days after the September 30 deadline.

For Pharmacists: Pharmacists have until the September 30 deadline to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Expect credit uploads to be completed within 5-7 business days after the evaluation deadline.

For questions regarding the evaluation, please contact:

cmhc_eval@ cardiometabolichealth.org

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found here.

DISCLOSURES

Information on planner and faculty disclosures are available here.

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

DISCLOSURE OF UNLABLED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.